<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31711481</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1423-0127</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Nov</Month><Day>11</Day></PubDate></JournalIssue><Title>Journal of biomedical science</Title><ISOAbbreviation>J Biomed Sci</ISOAbbreviation></Journal><ArticleTitle>Hypoxia and therapeutic treatment of EV-A71 with an immune modulator TLR7 agonist in a new immunocompetent mouse model.</ArticleTitle><Pagination><StartPage>93</StartPage><MedlinePgn>93</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">93</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12929-019-0585-y</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Enterovirus 71 (EV71 or EV-A71) was first identified in California about half a century ago. In recent years, outbreaks of EV-A71 were prevalent worldwide, including Taiwan, Malaysia, Singapore, Japan, and China. Between 2008 and 2011, China alone reported 1894 deaths associated with EV-A71 infection. In mild cases, EV-A71 can cause herpangina and hand-foot-and-mouth disease (HFMD). However, in severe cases, it could cause neurological disorders, including meningitis and encephalitis. Cardiopulmonary failure is common among hospitalized children with EV-A71 infection. No effective FDA-approved therapeutics against EV-A71 are clinically available.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We report the establishment of an immunocompetent wild type strain 129 (wt-129) mouse model, which can be cross-species infected with human EV-A71 clinical isolates via an intraperitoneal route.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">One intriguing disease phenotype of this new model is the development of characteristic "White-Jade" patches in the muscle, which lost sporadically the normal pink color of uninfected muscle. Viral VP1 protein and massive leukocyte infiltration were detected in muscles with or without white-jades. We demonstrated further that hypoxia is a general phenomenon associated with white-jades in both immunocompetent and immunodeficient mouse models. Therefore, hypoxia appears to be a feature intrinsic to EV-A71 infection, irrespective of its host's immunogenetic background. To date, no effective treatment for EV-A71 is available. Here, using this new wt-129 mouse model, we showed that timely treatment with compound R837 (a TLR7 immune modulator) via oral or intraperitoneal routes, rescued the hypoxia, limb paralysis, and death at a high therapeutic efficacy.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this new immunocompetent mouse 129 model, we observed an unexpected white-jade phenotype and its associated hypoxia. The successful treatment with TLR7 immune modulators via an oral route, provide us a new research direction for EV-A71 basic science and translational research. It remains an open issue whether R837 or its related compounds, will be a promising drug candidate in clinical trials in EV-A71 endemic or epidemic areas in the future.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liou</LastName><ForeName>An-Ting</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Chun-Che</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chou</LastName><ForeName>Shu-Fan</ForeName><Initials>SF</Initials><AffiliationInfo><Affiliation>Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Ya-Shu</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Chih-Shin</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shih</LastName><ForeName>Chiaho</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-6902-0593</Identifier><AffiliationInfo><Affiliation>Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan. cshih@ibms.sinica.edu.tw.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AS-SUMMIT-108</GrantID><Agency>Academia Sinica</Agency><Country/></Grant><Grant><GrantID>106-2320-B-001- 010</GrantID><Agency>Ministry of Science and Technology, Taiwan</Agency><Country/></Grant><Grant><GrantID>106-0210-01-15-02</GrantID><Agency>Ministry of Science and Technology, Taiwan</Agency><Country/></Grant><Grant><GrantID>107-0210-01-19-01</GrantID><Agency>Ministry of Science and Technology, Taiwan</Agency><Country/></Grant><Grant><GrantID>108-3114-Y-001-002</GrantID><Agency>Ministry of Science and Technology, Taiwan</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>11</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Biomed Sci</MedlineTA><NlmUniqueID>9421567</NlmUniqueID><ISSNLinking>1021-7770</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495348">TLR7 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051199">Toll-Like Receptor 7</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000693" MajorTopicYN="N">Anaerobiosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007121" MajorTopicYN="N">Immunocompetence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051199" MajorTopicYN="N">Toll-Like Receptor 7</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EV-A71</Keyword><Keyword MajorTopicYN="N">White-Jade muscle</Keyword><Keyword MajorTopicYN="N">enterovirus</Keyword><Keyword MajorTopicYN="N">hypoxia</Keyword><Keyword MajorTopicYN="N">mouse model</Keyword><Keyword MajorTopicYN="N">therapy</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>11</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31711481</ArticleId><ArticleId IdType="pmc">PMC6849267</ArticleId><ArticleId IdType="doi">10.1186/s12929-019-0585-y</ArticleId><ArticleId IdType="pii">10.1186/s12929-019-0585-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shih C, Liao CC, Chang YS, Wu SY, Chang CS, Liou AT. Immunocompetent and Immunodeficient Mouse Models for Enterovirus 71 Pathogenesis and Therapy. Viruses. 2018;10(12):674. doi: 10.3390/v10120674.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v10120674</ArticleId><ArticleId IdType="pmc">PMC6316343</ArticleId><ArticleId IdType="pubmed">30487421</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox JA, Hiscox JA, Solomon T, Ooi MH, Ng LFP. Immunopathogenesis and virus-host interactions of Enterovirus 71 in patients with hand, Foot and Mouth Disease. Front Microbiol. 2017;8:2249. doi: 10.3389/fmicb.2017.02249.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2017.02249</ArticleId><ArticleId IdType="pmc">PMC5713468</ArticleId><ArticleId IdType="pubmed">29238324</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn G, Klapsa D, Wilton T, Stone L, Minor PD, Martin J. Twenty-eight years of poliovirus replication in an Immunodeficient individual: impact on the global polio eradication initiative. PLoS Pathog. 2015;11(8):e1005114. doi: 10.1371/journal.ppat.1005114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1005114</ArticleId><ArticleId IdType="pmc">PMC4552295</ArticleId><ArticleId IdType="pubmed">26313548</ArticleId></ArticleIdList></Reference><Reference><Citation>Racaniello VR. One hundred years of poliovirus pathogenesis. Virology. 2006;344(1):9&#x2013;16. doi: 10.1016/j.virol.2005.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2005.09.015</ArticleId><ArticleId IdType="pubmed">16364730</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggen J, Thibaut HJ, Strating J, van Kuppeveld FJM. The life cycle of non-polio enteroviruses and how to target it. Nat Rev Microbiol. 2018;16(6):368&#x2013;381. doi: 10.1038/s41579-018-0005-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-018-0005-4</ArticleId><ArticleId IdType="pubmed">29626210</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Z, Hensley L, McKnight KL, Hu F, Madden V, Ping L, et al. A pathogenic picornavirus acquires an envelope by hijacking cellular membranes. Nature. 2013;496(7445):367&#x2013;371. doi: 10.1038/nature12029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12029</ArticleId><ArticleId IdType="pmc">PMC3631468</ArticleId><ArticleId IdType="pubmed">23542590</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, et al. An epidemic of Enterovirus 71 infection in Taiwan. N Engl J Med. 1999;341:929&#x2013;935. doi: 10.1056/NEJM199909233411301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199909233411301</ArticleId><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>Lum LC, Wong KT, Lam SK, Chua KB, Goh AY, Lim WL, et al. Fatal enterovirus 71 encephalomyelitis. J Pediatr. 1998;133(6):795&#x2013;798. doi: 10.1016/S0022-3476(98)70155-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-3476(98)70155-6</ArticleId><ArticleId IdType="pubmed">9842048</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng KF, Chen LL, Huang PN, Shih SR. Neural pathogenesis of enterovirus 71 infection. Microbes Infect. 2010;12(7):505&#x2013;510. doi: 10.1016/j.micinf.2010.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2010.03.006</ArticleId><ArticleId IdType="pubmed">20348010</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo ST, Chiang PS, Chung WY, Chia MY, Tsao KC, Wang YH, et al. Reemergence of enterovirus 71 epidemic in northern Taiwan, 2012. PLoS One. 2015;10(3):e0116322. doi: 10.1371/journal.pone.0116322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0116322</ArticleId><ArticleId IdType="pmc">PMC4361668</ArticleId><ArticleId IdType="pubmed">25774888</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander JP, Jr, Baden L, Pallansch MA, Anderson LJ. Enterovirus 71 infections and neurologic disease--United States, 1977-1991. J Infect Dis. 1994;169(4):905&#x2013;908. doi: 10.1093/infdis/169.4.905.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/169.4.905</ArticleId><ArticleId IdType="pubmed">8133108</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer TK, Nielsen AY, Sydenham TV, Andersen PH, Andersen B, Midgley SE. Emergence of enterovirus 71 C4a in Denmark, 2009 to 2013. Euro Surveillance. 2014;19(38):6.</Citation><ArticleIdList><ArticleId IdType="pubmed">25306878</ArticleId></ArticleIdList></Reference><Reference><Citation>Medici MC, Tummolo F, Arcangeletti MC, Conto FD, Chezzi C, Dodi I, et al. A cluster of Enterovirus 71 subgenogroup C2 in a nursery school, Italy, 2014. New Microbiol. 2016;39(4):4.</Citation><ArticleIdList><ArticleId IdType="pubmed">27455182</ArticleId></ArticleIdList></Reference><Reference><Citation>Akhmadishina LV, Eremeeva TP, Trotsenko OE, Ivanova OE, Mikhailov MI, Lukashev AN. Seroepidemiology and molecular epidemiology of enterovirus 71 in Russia. PLoS One. 2014;9(5):e97404. doi: 10.1371/journal.pone.0097404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0097404</ArticleId><ArticleId IdType="pmc">PMC4018281</ArticleId><ArticleId IdType="pubmed">24819617</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, Takemura T, et al. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med. 2009;15(7):798&#x2013;801. doi: 10.1038/nm.1992.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1992</ArticleId><ArticleId IdType="pubmed">19543282</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, Shimizu H. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med. 2009;15(7):794&#x2013;797. doi: 10.1038/nm.1961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1961</ArticleId><ArticleId IdType="pubmed">19543284</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang SL, Chou YT, Wu CN, Ho MS. Annexin II binds to capsid protein VP1 of enterovirus 71 and enhances viral infectivity. J Virol. 2011;85(22):11809&#x2013;11820. doi: 10.1128/JVI.00297-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00297-11</ArticleId><ArticleId IdType="pmc">PMC3209289</ArticleId><ArticleId IdType="pubmed">21900167</ArticleId></ArticleIdList></Reference><Reference><Citation>Su PY, Wang YF, Huang SW, Lo YC, Wang YH, Wu SR, et al. Cell surface nucleolin facilitates enterovirus 71 binding and infection. J Virol. 2015;89(8):4527&#x2013;4538. doi: 10.1128/JVI.03498-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03498-14</ArticleId><ArticleId IdType="pmc">PMC4442404</ArticleId><ArticleId IdType="pubmed">25673703</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii K, Nagata N, Sato Y, Ong KC, Wong KT, Yamayoshi S, et al. Transgenic mouse model for the study of enterovirus 71 neuropathogenesis. Proc Natl Acad Sci U S A. 2013;110(36):14753&#x2013;14758. doi: 10.1073/pnas.1217563110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1217563110</ArticleId><ArticleId IdType="pmc">PMC3767555</ArticleId><ArticleId IdType="pubmed">23959904</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YW, Yu SL, Shao HY, Lin HY, Liu CC, Hsiao KN, et al. Human SCARB2 transgenic mice as an infectious animal model for enterovirus 71. PLoS One. 2013;8(2):e57591. doi: 10.1371/journal.pone.0057591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0057591</ArticleId><ArticleId IdType="pmc">PMC3581494</ArticleId><ArticleId IdType="pubmed">23451246</ArticleId></ArticleIdList></Reference><Reference><Citation>Khong WX, Yan B, Yeo H, Tan EL, Lee JJ, Ng JK, et al. A non-mouse-adapted enterovirus 71 (EV71) strain exhibits neurotropism, causing neurological manifestations in a novel mouse model of EV71 infection. J Virol. 2012;86(4):2121&#x2013;2131. doi: 10.1128/JVI.06103-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.06103-11</ArticleId><ArticleId IdType="pmc">PMC3302383</ArticleId><ArticleId IdType="pubmed">22130542</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng T, Kwang J. Attenuation of human enterovirus 71 high-replication-fidelity variants in AG129 mice. J Virol. 2014;88(10):5803&#x2013;5815. doi: 10.1128/JVI.00289-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00289-14</ArticleId><ArticleId IdType="pmc">PMC4019108</ArticleId><ArticleId IdType="pubmed">24623423</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia Q, Ng Q, Chin W, Meng T, Chow VTK, Wang CI, et al. Effective in vivo therapeutic IgG antibody against VP3 of enterovirus 71 with receptor-competing activity. Sci Rep. 2017;7:46402. doi: 10.1038/srep46402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep46402</ArticleId><ArticleId IdType="pmc">PMC5395816</ArticleId><ArticleId IdType="pubmed">28422137</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao CC, Liou AT, Chang YS, Wu SY, Chang CS, Lee CK, et al. Immunodeficient mouse models with different disease profiles by in vivo infection with the same clinical isolate of enterovirus 71. J Virol. 2014;88(21):12485&#x2013;12499. doi: 10.1128/JVI.00692-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00692-14</ArticleId><ArticleId IdType="pmc">PMC4248922</ArticleId><ArticleId IdType="pubmed">25142603</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C-S, Liao C-C, Liou A-T, Chang Y-S, Chang Y-T, Tzeng B-H, et al. Enterovirus 71 targets the cardiopulmonary system in a robust oral infection mouse model. Sci Rep. 2019;9(1):1. doi: 10.1038/s41598-018-37186-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-37186-2</ArticleId><ArticleId IdType="pmc">PMC6668393</ArticleId><ArticleId IdType="pubmed">31366973</ArticleId></ArticleIdList></Reference><Reference><Citation>Liou AT, Wu SY, Liao CC, Chang YS, Chang CS, Shih C. A new animal model containing human SCARB2 and lacking stat-1 is highly susceptible to EV71. Sci Rep. 2016;6:31151. doi: 10.1038/srep31151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep31151</ArticleId><ArticleId IdType="pmc">PMC4976353</ArticleId><ArticleId IdType="pubmed">27499235</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang WW, Young MP, Mamidi A, Regla-Nava JA, Kim K, Shresta S. A mouse model of Zika virus sexual transmission and vaginal viral replication. Cell Rep. 2016;17(12):3091&#x2013;3098. doi: 10.1016/j.celrep.2016.11.070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2016.11.070</ArticleId><ArticleId IdType="pmc">PMC5193244</ArticleId><ArticleId IdType="pubmed">28009279</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi SL, Tesh RB, Azar SR, Muruato AE, Hanley KA, Auguste AJ, et al. Characterization of a novel murine model to study Zika virus. Am J Trop Med Hyg. 2016;94(6):1362&#x2013;1369. doi: 10.4269/ajtmh.16-0111.</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.16-0111</ArticleId><ArticleId IdType="pmc">PMC4889758</ArticleId><ArticleId IdType="pubmed">27022155</ArticleId></ArticleIdList></Reference><Reference><Citation>Duggal NK, Ritter JM, Pestorius SE, Zaki SR, Davis BS, Chang GJ, et al. Frequent Zika virus sexual transmission and prolonged viral RNA shedding in an Immunodeficient mouse model. Cell Rep. 2017;18(7):1751&#x2013;1760. doi: 10.1016/j.celrep.2017.01.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.01.056</ArticleId><ArticleId IdType="pmc">PMC5683178</ArticleId><ArticleId IdType="pubmed">28199846</ArticleId></ArticleIdList></Reference><Reference><Citation>Semenza GL, Wang GL. A nuclear factor induced by hypoxia via De novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol. 1992;12:8. doi: 10.1128/MCB.12.12.5447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.12.12.5447</ArticleId><ArticleId IdType="pmc">PMC360482</ArticleId><ArticleId IdType="pubmed">1448077</ArticleId></ArticleIdList></Reference><Reference><Citation>Maxwell PH, Pugh CW, Ratcliffe PJ. Inducible operation of the erythropoietin 3&#x2019; enhancer in multiple cell lines: evidence for a widespread oxygen-sensing mechanism. Proc Natl Acad Sci U S A. 1993;90:5. doi: 10.1073/pnas.90.6.2423.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.90.6.2423</ArticleId><ArticleId IdType="pmc">PMC46099</ArticleId><ArticleId IdType="pubmed">8460154</ArticleId></ArticleIdList></Reference><Reference><Citation>Iliopoulos O, Levy AP, Jiang C, Kaelin WG, Jr, Goldberg MA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A. 1996;93(20):10595&#x2013;10599. doi: 10.1073/pnas.93.20.10595.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.93.20.10595</ArticleId><ArticleId IdType="pmc">PMC38198</ArticleId><ArticleId IdType="pubmed">8855223</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell EL, Bruyninckx WJ, Kelly CJ, Glover LE, McNamee EN, Bowers BE, et al. Transmigrating neutrophils shape the mucosal microenvironment through localized oxygen depletion to influence resolution of inflammation. Immunity. 2014;40(1):66&#x2013;77. doi: 10.1016/j.immuni.2013.11.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2013.11.020</ArticleId><ArticleId IdType="pmc">PMC3951457</ArticleId><ArticleId IdType="pubmed">24412613</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Zhao B, Chen X, Song N, Wu J, Li G, et al. GS-9620 inhibits enterovirus 71 replication mainly through the NF-kappaB and PI3K-AKT signaling pathways. Antivir Res. 2018;153:39&#x2013;48. doi: 10.1016/j.antiviral.2018.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2018.02.002</ArticleId><ArticleId IdType="pubmed">29425831</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg K, Corona BT, Walters TJ. Therapeutic strategies for preventing skeletal muscle fibrosis after injury. Front Pharmacol. 2015;6:87. doi: 10.3389/fphar.2015.00087.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2015.00087</ArticleId><ArticleId IdType="pmc">PMC4404830</ArticleId><ArticleId IdType="pubmed">25954202</ArticleId></ArticleIdList></Reference><Reference><Citation>Tidball JG. Inflammatory processes in muscle injury and repair. Am J Phys Regul Integr Comp Phys. 2005;288(2):R345&#x2013;R353.</Citation><ArticleIdList><ArticleId IdType="pubmed">15637171</ArticleId></ArticleIdList></Reference><Reference><Citation>Rankin EB, Giaccia AJ. Hypoxic control of metastasis. Science. 2016;352(6282):175&#x2013;180. doi: 10.1126/science.aaf4405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf4405</ArticleId><ArticleId IdType="pmc">PMC4898055</ArticleId><ArticleId IdType="pubmed">27124451</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazear HM, Daniels BP, Pinto AK, Huang AC, Vick SC, Doyle SE, et al. Interferon-lambda restricts West Nile virus neuroinvasion by tightening the blood-brain barrier. Sci Transl Med. 2015;7(284):284ra59. doi: 10.1126/scitranslmed.aaa4304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaa4304</ArticleId><ArticleId IdType="pmc">PMC4435724</ArticleId><ArticleId IdType="pubmed">25904743</ArticleId></ArticleIdList></Reference><Reference><Citation>Wack A, Terczynska-Dyla E, Hartmann R. Guarding the frontiers: the biology of type III interferons. Nat Immunol. 2015;16(8):802&#x2013;809. doi: 10.1038/ni.3212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3212</ArticleId><ArticleId IdType="pmc">PMC7096991</ArticleId><ArticleId IdType="pubmed">26194286</ArticleId></ArticleIdList></Reference><Reference><Citation>Beutner KR, Spruance SL, Hougham AJ, Fox TL, Owens ML, Douglas JM. Treatment of genital warts with an immune-response modifier (imiquimod) J Am Acad Dermatol. 1998;38:10. doi: 10.1016/S0190-9622(98)70243-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0190-9622(98)70243-9</ArticleId><ArticleId IdType="pubmed">9486679</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiley D, Douglas J, Beutner K, Cox T, Fife K, Moscicki A, et al. External genital warts: diagnosis, treatment, and prevention. Clin Infect Dis. 2002;35:15. doi: 10.1086/340743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/340743</ArticleId><ArticleId IdType="pubmed">12353208</ArticleId></ArticleIdList></Reference><Reference><Citation>De Clercq E, Li G. Approved antiviral drugs over the past 50 years. Clin Microbiol Rev. 2016;29(3):695&#x2013;747. doi: 10.1128/CMR.00102-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00102-15</ArticleId><ArticleId IdType="pmc">PMC4978613</ArticleId><ArticleId IdType="pubmed">27281742</ArticleId></ArticleIdList></Reference><Reference><Citation>Gane EJ, Lim YS, Gordon SC, Visvanathan K, Sicard E, Fedorak RN, et al. The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. J Hepatol. 2015;63(2):320&#x2013;328. doi: 10.1016/j.jhep.2015.02.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2015.02.037</ArticleId><ArticleId IdType="pubmed">25733157</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih C, Chou SF, Yang CC, Huang JY, Choijilsuren G, Jhou RS. Control and eradication strategies of hepatitis B virus. Trends Microbiol. 2016;24(9):739&#x2013;749. doi: 10.1016/j.tim.2016.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tim.2016.05.006</ArticleId><ArticleId IdType="pubmed">27287929</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih C, Yang CC, Choijilsuren G, Chang CH, Liou AT. Hepatitis B Virus. Trends Microbiol. 2018;26(4):386&#x2013;387. doi: 10.1016/j.tim.2018.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tim.2018.01.009</ArticleId><ArticleId IdType="pubmed">29500037</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YF, Chou CT, Lei HY, Liu CC, Wang SM, Yan JJ, et al. A mouse-adapted enterovirus 71 strain causes neurological disease in mice after oral infection. J Virol. 2004;78(15):7916&#x2013;7924. doi: 10.1128/JVI.78.15.7916-7924.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.15.7916-7924.2004</ArticleId><ArticleId IdType="pmc">PMC446098</ArticleId><ArticleId IdType="pubmed">15254164</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiu JH, Zhu H, Xu YF, Liu JN, Xia XZ, Zhang LF. Necrotizing myositis causes restrictive hypoventilation in a mouse model for human enterovirus 71 infection. Virol J. 2013;10:215. doi: 10.1186/1743-422X-10-215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-10-215</ArticleId><ArticleId IdType="pmc">PMC3710232</ArticleId><ArticleId IdType="pubmed">23809248</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, Huang LM, Gau SS, Wu YY, Hsia SH, Fan TY, et al. Neurodevelopment and cognition in children after enterovirus 71 infection. N Engl J Med. 2007;356(12):1226&#x2013;1234. doi: 10.1056/NEJMoa065954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa065954</ArticleId><ArticleId IdType="pubmed">17377160</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, Lin HY, Gau SS, Lu CY, Hsia SH, Huang YC, et al. Enterovirus A71 neurologic complications and long-term sequelae. J Biomed Sci. 2019;26(1):57. doi: 10.1186/s12929-019-0552-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-019-0552-7</ArticleId><ArticleId IdType="pmc">PMC6688366</ArticleId><ArticleId IdType="pubmed">31395054</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng H, Zeng J, Li H, Li Y, Wang W. Neuroimaging of HFMD infected by EV71. Radiol Infect Dis. 2015;1(2):103&#x2013;108. doi: 10.1016/j.jrid.2015.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jrid.2015.02.006</ArticleId></ArticleIdList></Reference><Reference><Citation>H-g L, Lao Q. The pulmonary complications associated with EV71-infected hand&#x2013;foot&#x2013;mouth disease. Radiol Infect Dis. 2017;4(4):137&#x2013;142. doi: 10.1016/j.jrid.2017.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jrid.2017.01.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren R, Racaniello VR. Poliovirus spreads from muscle to the central nervous system by neural pathways. J Infect Dis. 1992;166(4):747&#x2013;752. doi: 10.1093/infdis/166.4.747.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/166.4.747</ArticleId><ArticleId IdType="pubmed">1326581</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 2010;9(11):1097&#x2013;1105. doi: 10.1016/S1474-4422(10)70209-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70209-X</ArticleId><ArticleId IdType="pubmed">20965438</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng GZ, Li MQ, Li YQ, Wang XM, Chen QY, Wei HS. Severe hand-foot-mouth disease: a report of 3 autopsied cases. Chin J Clin Exp Pathol. 2011;27:4.</Citation></Reference><Reference><Citation>Hatfield RH, Mendelow AD, Perry RH, Alvarez LM, Modha P. Triphenyltetrazolium chloride (TTC) as a marker for ischaemic changes in rat brain following permanent middle cerebral artery occlusion. Neuropathol Appl Neurobiol. 1991;17(1):61&#x2013;67. doi: 10.1111/j.1365-2990.1991.tb00694.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2990.1991.tb00694.x</ArticleId><ArticleId IdType="pubmed">2057051</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridiandries A, Tan JT, Bursill CA. The Role of CC-Chemokines in the Regulation of Angiogenesis. Int J Mol Sci. 2016;17(11):1856. doi: 10.3390/ijms17111856.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms17111856</ArticleId><ArticleId IdType="pmc">PMC5133856</ArticleId><ArticleId IdType="pubmed">27834814</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoese B, Schmid JA. The complexity of NF-&#x3ba;B signaling in inflammation and cancer. Mol Cancer. 2013;12:15. doi: 10.1186/1476-4598-12-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1476-4598-12-15</ArticleId><ArticleId IdType="pmc">PMC3750319</ArticleId><ArticleId IdType="pubmed">23915189</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu ML, Lee YP, Wang YF, Lei HY, Liu CC, Wang SM, et al. Type I interferons protect mice against enterovirus 71 infection. J Gen Virol. 2005;86(Pt 12):3263&#x2013;3269. doi: 10.1099/vir.0.81195-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.81195-0</ArticleId><ArticleId IdType="pubmed">16298971</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, Ennis J, Turner JD, Chu JJ. Single dose of an adenovirus vectored mouse interferon-alpha protects mice from lethal EV71 challenge. Antivir Res. 2016;134:207&#x2013;215. doi: 10.1016/j.antiviral.2016.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2016.09.003</ArticleId><ArticleId IdType="pmc">PMC7113890</ArticleId><ArticleId IdType="pubmed">27623347</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Zhang X, Wang F, Wei H, Ma H, Sui M, et al. Clinical efficacy of therapy with recombinant human interferon alpha1b in hand, foot, and mouth disease with Enterovirus 71 infection. PLoS One. 2016;11(2):e0148907. doi: 10.1371/journal.pone.0148907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0148907</ArticleId><ArticleId IdType="pmc">PMC4755579</ArticleId><ArticleId IdType="pubmed">26882102</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H, Huang L, Zhou J, Lin K, Wang H, Xue X, et al. Efficacy and safety of interferon-alpha2b spray in the treatment of hand, foot, and mouth disease: a multicenter, randomized, double-blind trial. Arch Virol. 2016;161(11):3073&#x2013;3080. doi: 10.1007/s00705-016-3012-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-016-3012-7</ArticleId><ArticleId IdType="pubmed">27518403</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>